These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 17143694)

  • 1. Meta-analysis of the results of intravenous gamma globulin treatment of coronary artery lesions in Kawasaki disease.
    Mori M; Miyamae T; Imagawa T; Katakura S; Kimura K; Yokota S
    Mod Rheumatol; 2004; 14(5):361-6. PubMed ID: 17143694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
    Mori M; Imagawa T; Yasui K; Kanaya A; Yokota S
    J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin.
    Mori M; Imagawa T; Katakura S; Miyamae T; Okuyama K; Ito S; Nakamura T; Kimura H; Yokota S
    Mod Rheumatol; 2004; 14(1):43-7. PubMed ID: 17028804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.
    Terai M; Shulman ST
    J Pediatr; 1997 Dec; 131(6):888-93. PubMed ID: 9427895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous gamma-globulin therapy improves hypercytokinemia in the acute phase of Kawasaki disease.
    Kobayashi N; Mori M; Kobayashi Y; Miyamae T; Imagawa T; Okuyama T; Kurozumi H; Yokota S
    Mod Rheumatol; 2004 Dec; 14(6):447-52. PubMed ID: 24387721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy.
    Senzaki H; Kobayashi T; Nagasaka H; Nakano H; Kyo S; Yokote Y; Sasakid N
    Pediatr Res; 2003 Jun; 53(6):983-8. PubMed ID: 12621103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.
    Furukawa S; Matsubara T; Umezawa Y; Motohashi T; Ino T; Yabuta K
    Eur J Pediatr; 1994 Sep; 153(9):663-7. PubMed ID: 7957426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.
    Miura M; Ohki H; Tsuchihashi T; Yamagishi H; Katada Y; Yamada K; Yamashita Y; Sugaya A; Komiyama O; Shiro H
    Arch Dis Child; 2004 Aug; 89(8):776-80. PubMed ID: 15269082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness.
    Sato N; Sugimura T; Akagi T; Yamakawa R; Hashino K; Eto G; Iemura M; Ishii M; Kato H
    Pediatr Int; 1999 Feb; 41(1):1-7. PubMed ID: 10200128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease.
    Weng KP; Hsieh KS; Huang SH; Ou SF; Ma CY; Ho TY; Lai CR; Ger LP
    Kaohsiung J Med Sci; 2012 Jan; 28(1):23-9. PubMed ID: 22226058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of vascular leakage in acute Kawasaki disease.
    Terai M; Honda T; Yasukawa K; Higashi K; Hamada H; Kohno Y
    Circulation; 2003 Jul; 108(3):325-30. PubMed ID: 12835221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease.
    Morikawa Y; Ohashi Y; Harada K; Asai T; Okawa S; Nagashima M; Katoh T; Baba K; Furusho K; Okuni M; Osano M
    Pediatr Int; 2000 Oct; 42(5):464-9. PubMed ID: 11059532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum ferritin as a crucial biomarker in the diagnosis and prognosis of intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease: A systematic review and meta-analysis.
    Wen H; Hun M; Zhao M; Han P; He Q
    Front Med (Lausanne); 2022; 9():941739. PubMed ID: 36035423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease.
    Muta H; Ishii M; Furui J; Nakamura Y; Matsuishi T
    Acta Paediatr; 2006 Feb; 95(2):189-93. PubMed ID: 16449025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan.
    Muta H; Ishii M; Egami K; Furui J; Sugahara Y; Akagi T; Nakamura Y; Yanagawa H; Matsuishi T
    J Pediatr; 2004 Apr; 144(4):496-9. PubMed ID: 15069399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reappraisal of VEGF in the Pathogenesis of Kawasaki Disease.
    Chen CY; Huang SH; Chien KJ; Lai TJ; Chang WH; Hsieh KS; Weng KP
    Children (Basel); 2022 Sep; 9(9):. PubMed ID: 36138652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of intravenous gamma-globulin for Kawasaki disease: effects on cardiac sequelae.
    Yanagawa H; Nakamura Y; Sakata K; Yashiro M
    Pediatr Cardiol; 1997; 18(1):19-23. PubMed ID: 8960487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
    Wang Y; Wang W; Gong F; Fu S; Zhang Q; Hu J; Qi Y; Xie C; Zhang Y
    Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical manifestations and effects of IVGG in patients with Kawasaki disease].
    Hwang KP; Wu JR; Huang LY; Liou CC; Huang TY
    Kaohsiung J Med Sci; 1996 Mar; 12(3):159-66. PubMed ID: 8709183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albumin level and progression of coronary artery lesions in Kawasaki disease: A retrospective cohort study.
    Xia Y; Qiu H; Wen Z; Shi H; Yu H; Li J; Zhang Q; Wang J; Rong X; Wu R; Chu M
    Front Pediatr; 2022; 10():947059. PubMed ID: 36186633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.